WuXi Discovery Services

We are thrilled to share the highlights from our incredible experience at the 12th International Symposium on DNA-Encoded Chemical Libraries in Shanghai, China. Dr. Wenji Su, Head of Early Discovery Platform, WuXi Biology, delivered a compelling presentation on One-Bead-One-Compound (OBOC) DEL, which sparked great interest and positive feedback. In the flash talk session, Dr. Weiren Cui, Director of Hit Finding and Informatics, showcased our advancements in using DEL to enable molecular glue discovery. This event provided an exceptional platform for insightful exchanges and the forging of new connections within the DEL scientific community. We proudly displayed seven posters focused on how DEL enables new modality discovery and novel DEL chemistry, along with a stand that highlighted our comprehensive capabilities, innovative solutions, and expertise. We look forward to building on the relationships and ideas that emerged from this event and continuing our journey of innovation and collaboration. See you next year!

The safe production of cultivated plants is threatened by various fungal diseases. NIS1 is a secreted effector protein produced by fungal pathogens. BAK1 is a plant receptor-like kinase that plays a crucial role in recognizing pathogen-associated molecules like NIS1. Understanding the interaction between NIS1 and BAK1 is important for studying plant defense mechanisms against fungal pathogens, and manipulating this interaction could potentially lead to the development of strategies to enhance plant resistance to fungal diseases. A recent publication describes the identification of a novel molecule discovered directly from WuXi AppTec's DNA-encoded library (DEL) product. The authors demonstrate that this molecule can block the interaction of NIS1-BAK1 and significantly inhibit the virulence of the rice blast fungus, Magnaporthe oryzae. Click this link 👇 to view the abstract: https://lnkd.in/gR2pgv7u #Biotech #DEL #BAK1 #NIS1 #BRI1 #Oryzae #RiceBlast

The heme oxygenase (HO) family comprises the major isozymes HO-1 and HO-2, of which HO-1 is deemed as an emerging target for cancer therapy. HO-1 overexpression is often observed in prostate, renal, colon, lung, breast, and glioma cancers. In a recent publication, WuXi AppTec scientists report the discovery of five series of novel scaffold HO-1 inhibitors. Fourteen tested molecules showed more than 100-fold selectivity towards HO-1 over HO-2. Significantly, this study demonstrates the effectiveness of utilizing extensive DNA-encoded library (DEL) screening data in conjunction with deep learning models for the discovery of novel drug-like hits beyond the conventional DEL chemical space. Click this link 👇 to read the FULL article. https://lnkd.in/dirVcFbX #Biotech #DrugDiscovery #Cancer #ML #Heme #Oxygenase #DEL

Rheumatoid arthritis (RA) is a prevalent, chronic, autoimmune disease. The onset and progression of RA are closely associated with an aberrant immune response, in which immune cells accumulate excessively in target joints. Most current, anti-rheumatic drugs only alleviate disease progression or ameliorate inflammation. Development of new RA therapies with increased efficacy represents an unmet medical need. In a recent study, WuXi Biology utilized a collagen-induced arthritis mouse model to investigate the role of JAK inhibitors in RA pathogenesis. This study provides valuable insights into immune modulation and the potential benefits of selective JAK inhibitors in RA treatment. View 👇the video to learn more: https://lnkd.in/er5e2n-F #DrugDiscovery #Autoimmune #Rheumatoid #JAKinhibitors #Arthritis

The October edition of our Monthly Newsletter is here! 🔬✨ This month, we’re diving into exciting topics, including: 🔹 mRNA Drugs – Revolutionizing therapeutic possibilities 🔹 Peptide Optimization Strategies – Enhancing efficacy and stability 🔹 And much more! Stay informed with the latest science and strategies that can accelerate your drug discovery efforts. #DrugDiscovery #mRNADrugs #PeptideOptimization #Pharmaceuticals

Research on cancer immunotherapy has firmly established immune cells as key players in effective cancer treatment. Peptide vaccines directly targeting immune cells have demonstrated immense potential due to their specificity and applicability, but developing peptide vaccines to generate tumor-reactive T cells remains challenging. WuXi AppTec recently contributed to a review article discussing various elements of effective peptide vaccines, including antigen selection, peptide epitope optimization, vaccine adjuvants, and the combination of multiple immunotherapies. Click this link 👇 to view the abstract: https://lnkd.in/gywJRM6K #Biotech #DrugDiscovery #Peptides #PeptideVaccines #Immunotherapy

In recent years, bispecific antibodies (BsAbs) have emerged as a novel strategy in tumor immunotherapy. BsAbs combine two distinct antigen targets within a single antibody molecule, potentially enhancing clinical efficacy and safety. As a result of this dual targeting approach, the clinical therapeutic effects of BsAbs are considered superior to those of monoclonal antibodies. In our latest newsletter, WuXi AppTec scientists showcase a case study evaluating the PK/PD/safety profile of a BsAb that targets CD3 and Claudin18.2 (CLDN18.2). BsAbs that target both CD3 and CLDN18.2 bind to both CD3-expressing T cells and CLDN18.2-expressing tumor cells. This crosslinking activates T cells and causes them to lyse the tumor cells. Click this link 👇 to learn more. https://lnkd.in/gqgJPid3 #DrugDiscovery #Oncology #BispecificAntibody #BsAb #CD3 #NHP

Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in Western populations. Targeted therapies, including the use of BTK inhibitors, have significantly improved the care of patients with CLL. However, over time, many patients develop resistance to these drugs. Acquired resistance to the BTK inhibitor ibrutinib is mediated by the C481S mutation, which decreases binding affinity and changes binding from irreversible to reversible. Unlike C481S, which results in a kinase that retains activity, the L528W mutation in BTK prevents both the binding of covalent inhibitors and the binding of ATP. To bolster the research of innovative cancer drugs and to emulate real-world clinical scenarios of drug resistance, WuXi Biology has established REC1 lymphoma cell lines and animal models carrying the BTK C481S mutation or L528W mutation. Click this link 👇 to learn more. https://lnkd.in/g7Q_chGy #DrugDiscovery #Oncology #DrugResistance #BTK #Ibrutinib #REC1 #CLL #Lymphoma

Would you like to predict organic reaction outcomes accurately and design synthetic sequences with higher rates of success? Would you prefer to learn and rationalize organic chemistry in a data-driven manner? Quantum mechanics (QM) tools for chemistry are evolving at a tremendously fast pace and have proven to be invaluable for organic and medicinal chemists. We are excited to announce that the latest edition of our QM eBook, “Quantum Mechanics for Organic Chemists, An Experimentalist Approach” is now available! Click👇this link to request a copy of our 4th edition eBook: https://lnkd.in/g9DYGeZU #QM #QuantumChemistry #MedicinalChemistry #OrganicChemistry #RCS #ResearchChemistryServices #DiscoveryChemistry #SpecialtyChemistry

Cereblon (CRBN) forms an E3 ligase complex together with DDB1, CUL4, and RBX1. CRBN functions as a substrate receptor of this complex, and this protein is a key target for the action of small molecules. Targeting of CRBN can modify its substrate specificity towards non-physiological proteins, which are subsequently ubiquitinated and degraded by the proteasome. To support the discovery of CRBN-DDB1 PROTACs® and molecular glues, WuXi AppTec offers a comprehensive platform of ready-to-go biophysical assays, high-quality protein production, and established X-ray crystallography protocols. Click ⬇️ to learn more https://lnkd.in/eWnypVwe #Biophysical #Crystallography #StructuralBiology #nanoDSF #MST #CRBN #E3Ligase #DDB1 #PROTAC #MolecularGlues